KRRO-110 miss drives overhaul; KRRO-121/111 show preclinical promise. Click here to read my most recent analysis of the stock ...
New research results show that a new form of gene editing is efficient in correcting a mutation in patient cells with the monogenic disease Alpha-1 antitrypsin deficiency (AATD), a common inherited ...
Zacks Investment Research on MSN
Beam Therapeutics stock soars 21% in three months: Here's why
Shares of Beam Therapeutics BEAM have risen 21% over the past three months against the industry’s 4.5% decline, primarily ...
AATD is a genetic disease that can affect the liver or lung. Patients lack the alpha-1 protein (made by the liver) which is designed to protect tissues in the body from being attacked by its own ...
CAMBRIDGE, Mass., May 12, 2026--(BUSINESS WIRE)--AIRNA, a biotech company pioneering RNA-editing therapeutics to transform the lives of patients with rare and common conditions, is presenting new ...
Prime Medicine's Prime Editing is a much more credible tool for other larger TAMs like Wilson Disease and AATD. See why PRME ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Recent studies attempted to improve the risk of recurrence while reducing the risk of adverse effect Alvelestat is an investigational oral neutrophil elastase inhibitor designed to protect AATD ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results